Neo Part 2 Flashcards

1
Q

Familial cancers

A

Breast
Ovarian
Colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Inhereted autosomal dominant cancer

A

Familial retinoblastoma (40% familial)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Autosomal recessive

A

Xerodermal pigmentosim

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Features that characterize familial cancers include:

A

early age at onset
tumors arising in two or more close relatives
sometimes multiple or bilateral tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

cancers that are not associated with specific marker phenotypes, e.g. The transmission pattern is not clear.

A

Familial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

cancers can be linked to the inheritance of mutant genes. Examples include linkage of BRCA1 and BRCA2 genes to familial breast and ovarian cancers.

A

Familial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Acquired Preneoplastic Disorders

A

Regenerative
Hyperplastic

Atrophic

Ulcerative

Dysplastic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Acquired Preneoplastic Disorders in:

hepatocellular carcinoma in

endometrial carcinoma in

Lung cancer in

gastric carcinoma in

colorectal carcinoma in

A

Regenerative (e.g. hepatocellular carcinoma in cirrhosis)
Hyperplastic (e.g. endometrial carcinoma in endometrial hyperplasia)
Dysplastic (e.g. Lung cancer in bronchial dysplasia)
Atrophic (e.g. gastric carcinoma in atrophic gastritis)
Ulcerative (e.g. colorectal carcinoma in ulcerative colitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Clinical Features of Neoplasia

A
Local effect
   Pressure effect
   Functional activity (e.g. hormone synthesis)
   Bleeding
   Infection
Cachexia (wasting) 
Paraneoplastic syndromes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

loss of body fat and body mass associated with weakness, anorexia, and anemia
Often correlates with tumor size and extent of metastases

A

Cachexia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Origin of cancer cachexia is multifactorial:

A

reduced calorie intake due to loss of appetite
increase in basal metabolic rate
central effects of tumor on hypothalamus, probably related to macrophage production of TNF & IL-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Symptoms other than cachexia that cannot be explained by local or distant spread of the tumor They appear in 10-15% of patients with cancer

A

Paraneoplastic Syndromes

Most common ones: hypercalcemia, Cushing syndrome, and nonbacterial thrombotic endocarditis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Paraneoplastic Syndromes Often associated with the following neoplasms:

A

bronchogenic and breast cancers and hematologic malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Paraneoplastic Syndromes

A
Endocrinopathies
Neuromyopathies
Osteochondral Disorders
Vascular Phenomena
Fever
Nephrotic Syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cushing’s Syndrome

Mechanism and example

A

ACTH Like substance

Lung oat cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hyponatremia Mechanism and example

A

Inappropriate ADH secretion

Lung oat cell carcinoma

17
Q

Trousseau’s Syndrome

Mechanism and example

A

Hyper coagulable state

Various carcinomas

18
Q

Endocrinopathies

A

Hypercalcemia

Hypoglycemia

Carcinoid syndrome

Polycythemia

WDHA syndrome watery diarrhea, hypokalemia, and achlorhydria

19
Q

Causes of hypercalcemia in cancer:

A

Hormonal (e.g. PTHrP synthesis in squamous cell lung carcinomas)
Osteolytic metastatic disease of bone (e.g. metastatic breast carcinoma)
Tumor-derived factors (e.g. TGF-α, that activates osteoclasts and the active form of vitamin D)

20
Q

Hypoglycemia - caused by

A

tumor over-production of insulin or insulin like activities

Fibrosarcoma, Cerebellar hemangioma, Hepatocarcinoma

21
Q

Carcinoid syndrome - Caused by

A

serotonin and bradykinin produced by the tumor

Bronchial carcinoids, Pancreatic carcinoma, Carcinoid tumors of the bowel

22
Q

Neuromyopathies

A

Myasthenia - A block in neuromuscular transmission possibly caused by host antibodies against the tumor cells
(e.g. Bronchogenic carcinoma)

23
Q

Osteochondral Disorders

A

Hypertrophic osteoarthropathy and clubbing of the fingers

e.g. Bronchogenic carcinoma

24
Q

Vascular & hematoligical changes

A

Hyper-coagulability leading to:
venous thrombosis (Trousseau’s phenomenon) e.g.Pancreatic and bronchogenic carcinomas
nonbacterial thrombotic endocarditis
e.g. sterile vegetations on valves that occur with advanced carcinomas.
Anemia (e.g. Thymic neoplasms)

25
Q

Fever

A

Associated with bacterial infections
Common where blockage of drainage occurs
Not associated with infection
Likely caused by response to necrotic tumor cells and/or immune response to necrotic tumor proteins.

26
Q

Nephrotic Syndrome

A

probably caused by damage to renal glomeruli by tumor antigen-antibody complexes.

27
Q

What Are The Final Complications Of Malignancy (Causes Of Death)

A
metastases
cachexia
severe anemia, throbocytopeina
hypercoagulability
rupture into major vessels e.g. bleeding
compression of vital organs
organ failure e.g. renal failure
infection e.g. pneumonia
28
Q

Tumor Diagnosis

A
History and Clinical examination
Imaging - X-Ray, US, CT, MRI
Tumor markers- laboratory analysis 
Cytology –Pap smear, FNAB
Biopsy - Histopathology.
Molecular Tech – Gene detection.

Immunohistochemistry
Flow cytometry
Electron microscopy
In Situ Hybridization

29
Q

Tumor markers: sometimes diagnostic or prognostic

Some serological markers associated with malignant tumors

A
hCG
AFP
Calcitonin 
Prolactin
CA 125
PSA
30
Q

hCG associated with

A

Choriocarcinoma

31
Q

AFP

A

hepatocellular carcinoma

32
Q

Calcitonin

A

Thyroid medullary carcinoma

33
Q

Prolactin

A

Pituitary adenomas

34
Q

CA 125

A

Ovarian cancer

35
Q

PSA

A

prostate carcinoma